CRISPR–Cas9 technology is a powerful tool for immune cell engineering. Ex vivo editing has progressed to clinical trials, but in vivo applications are still limited owing to delivery challenges. This Review summarizes these challenges as well as strategies and progress in delivering CRISPR–Cas9 to immune and non-immune cells.
- Shahad K. Alsaiari
- Behnaz Eshaghi
- Ana Jaklenec